/**
 * ICH Guidelines Utility
 * 
 * This utility provides access to International Council for Harmonisation (ICH)
 * guidelines that are relevant to CTD submissions and eCTD format requirements.
 * It maps CTD sections to their corresponding ICH guidelines.
 */

// ICH Guidelines collection
const ichGuidelines = {
  // Quality Guidelines
  "Q1A": {
    title: "Stability Testing of New Drug Substances and Products",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.7", "3.2.P.8"],
    description: "Defines stability testing requirements for new drug substances and products"
  },
  "Q1B": {
    title: "Stability Testing: Photostability Testing of New Drug Substances and Products",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.7.3", "3.2.P.8.3"],
    description: "Provides recommendations for photostability testing"
  },
  "Q1C": {
    title: "Stability Testing for New Dosage Forms",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.P.8"],
    description: "Extends stability testing recommendations to new dosage forms"
  },
  "Q1D": {
    title: "Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.7", "3.2.P.8"],
    description: "Provides guidance on reduced stability testing designs"
  },
  "Q1E": {
    title: "Evaluation of Stability Data",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.7.3", "3.2.P.8.3"],
    description: "Guidance on evaluating stability data for shelf-life determination"
  },
  "Q2": {
    title: "Validation of Analytical Procedures",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.4.3", "3.2.P.5.3"],
    description: "Recommendations for validation of analytical procedures"
  },
  "Q3A": {
    title: "Impurities in New Drug Substances",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.3.2"],
    description: "Guidance on impurities in new drug substances"
  },
  "Q3B": {
    title: "Impurities in New Drug Products",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.P.5.5"],
    description: "Guidance on impurities in new drug products"
  },
  "Q3C": {
    title: "Impurities: Guideline for Residual Solvents",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.3.2", "3.2.P.5.5"],
    description: "Recommendations for residual solvent limits in pharmaceuticals"
  },
  "Q4B": {
    title: "Evaluation and Recommendation of Pharmacopoeial Texts",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.4.1", "3.2.P.5.1"],
    description: "Guidance on use of pharmacopoeial methods across ICH regions"
  },
  "Q5A": {
    title: "Viral Safety Evaluation of Biotechnology Products",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.A.2"],
    description: "Recommendations for viral safety evaluation of biotech products"
  },
  "Q5B": {
    title: "Quality of Biotechnological Products: Analysis of the Expression Construct",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.2.6"],
    description: "Guidance on characterizing expression constructs in biotech products"
  },
  "Q5C": {
    title: "Quality of Biotechnological Products: Stability Testing",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.7", "3.2.P.8"],
    description: "Stability testing recommendations for biotech products"
  },
  "Q5D": {
    title: "Derivation and Characterisation of Cell Substrates",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.2.3"],
    description: "Guidance on characterizing cell substrates used in production"
  },
  "Q5E": {
    title: "Comparability of Biotechnological/Biological Products",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.2.6", "3.2.P.2.3"],
    description: "Guidance on demonstrating comparability after manufacturing changes"
  },
  "Q6A": {
    title: "Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and Products",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.4", "3.2.P.5"],
    description: "Guidance on setting specifications for new drug substances and products"
  },
  "Q6B": {
    title: "Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.4", "3.2.P.5"],
    description: "Guidance on setting specifications for biotech products"
  },
  "Q7": {
    title: "Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.2.1"],
    description: "GMP guidance for API manufacturing"
  },
  "Q8": {
    title: "Pharmaceutical Development",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.P.2"],
    description: "Guidance on pharmaceutical development using Quality by Design principles"
  },
  "Q9": {
    title: "Quality Risk Management",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.P.2", "3.2.P.3"],
    description: "Guidance on quality risk management approaches"
  },
  "Q10": {
    title: "Pharmaceutical Quality System",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.2", "3.2.P.3"],
    description: "Framework for effective quality management systems"
  },
  "Q11": {
    title: "Development and Manufacture of Drug Substances",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S.2"],
    description: "Guidance on development and manufacturing of drug substances"
  },
  "Q12": {
    title: "Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management",
    url: "https://ich.org/page/quality-guidelines",
    sections: ["3.2.S", "3.2.P"],
    description: "Framework for management of post-approval CMC changes"
  },
  
  // Safety Guidelines
  "S1A": {
    title: "Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals",
    url: "https://ich.org/page/safety-guidelines",
    sections: ["4.2.3.4"],
    description: "Guidance on when carcinogenicity studies are needed"
  },
  "S1B": {
    title: "Testing for Carcinogenicity of Pharmaceuticals",
    url: "https://ich.org/page/safety-guidelines",
    sections: ["4.2.3.4"],
    description: "Recommendations for carcinogenicity testing approaches"
  },
  "S1C": {
    title: "Dose Selection for Carcinogenicity Studies of Pharmaceuticals",
    url: "https://ich.org/page/safety-guidelines",
    sections: ["4.2.3.4"],
    description: "Guidance on dose selection for carcinogenicity studies"
  },
  "S2": {
    title: "Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals",
    url: "https://ich.org/page/safety-guidelines",
    sections: ["4.2.3.3"],
    description: "Recommendations for genotoxicity testing strategy"
  },
  "S3A": {
    title: "Note for Guidance on Toxicokinetics: Assessment of Systemic Exposure in Toxicity Studies",
    url: "https://ich.org/page/safety-guidelines",
    sections: ["4.2.2", "4.2.3"],
    description: "Guidance on toxicokinetic evaluation within toxicity studies"
  },
  "S3B": {
    title: "Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies",
    url: "https://ich.org/page/safety-guidelines",
    sections: ["4.2.2"],
    description: "Recommendations for tissue distribution studies"
  },
  "S4": {
    title: "Duration of Chronic Toxicity Testing in Animals",
    url: "https://ich.org/page/safety-guidelines",
    sections: ["4.2.3.2"],
    description: "Guidance on duration of chronic toxicity studies"
  },
  "S5": {
    title: "Detection of Toxicity to Reproduction for Human Pharmaceuticals",
    url: "https://ich.org/page/safety-guidelines",
    sections: ["4.2.3.5"],
    description: "Recommendations for reproductive toxicity testing"
  },
  "S6": {
    title: "Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals",
    url: "https://ich.org/page/safety-guidelines",
    sections: ["4.2"],
    description: "Guidance on nonclinical testing of biotech products"
  },
  "S7A": {
    title: "Safety Pharmacology Studies for Human Pharmaceuticals",
    url: "https://ich.org/page/safety-guidelines",
    sections: ["4.2.1.3"],
    description: "Guidance on core battery of safety pharmacology studies"
  },
  "S7B": {
    title: "The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals",
    url: "https://ich.org/page/safety-guidelines",
    sections: ["4.2.1.3"],
    description: "Guidance on assessing QT prolongation risk in nonclinical studies"
  },
  "S8": {
    title: "Immunotoxicity Studies for Human Pharmaceuticals",
    url: "https://ich.org/page/safety-guidelines",
    sections: ["4.2.3.7.2"],
    description: "Recommendations for immunotoxicity evaluation"
  },
  "S9": {
    title: "Nonclinical Evaluation for Anticancer Pharmaceuticals",
    url: "https://ich.org/page/safety-guidelines",
    sections: ["4.2"],
    description: "Guidance on nonclinical testing of anticancer drugs"
  },
  "S10": {
    title: "Photosafety Evaluation of Pharmaceuticals",
    url: "https://ich.org/page/safety-guidelines",
    sections: ["4.2.3.7"],
    description: "Recommendations for photosafety assessment"
  },
  "S11": {
    title: "Nonclinical Safety Testing in Support of Development of Paediatric Medicines",
    url: "https://ich.org/page/safety-guidelines",
    sections: ["4.2.3.5.4"],
    description: "Guidance on juvenile animal studies for pediatric medicines"
  },
  
  // Efficacy Guidelines
  "E1": {
    title: "The Extent of Population Exposure to Assess Clinical Safety",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5"],
    description: "Recommendations for patient exposure to support safety evaluation"
  },
  "E2A": {
    title: "Clinical Safety Data Management: Definitions and Standards for Expedited Reporting",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5"],
    description: "Guidance on adverse event reporting during clinical trials"
  },
  "E2B": {
    title: "Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5"],
    description: "Specifications for electronic transmission of safety reports"
  },
  "E2C": {
    title: "Periodic Benefit-Risk Evaluation Report",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.6"],
    description: "Guidance on periodic safety update reports"
  },
  "E2D": {
    title: "Post-approval Safety Data Management",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.6"],
    description: "Recommendations for postmarketing safety data handling"
  },
  "E2F": {
    title: "Development Safety Update Report",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5"],
    description: "Guidance on annual safety reports during development"
  },
  "E3": {
    title: "Structure and Content of Clinical Study Reports",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5"],
    description: "Detailed guidance on format and content of clinical study reports"
  },
  "E4": {
    title: "Dose-Response Information to Support Drug Registration",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5", "2.7.3"],
    description: "Guidance on dose-response studies and analysis"
  },
  "E5": {
    title: "Ethnic Factors in the Acceptability of Foreign Clinical Data",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5.3"],
    description: "Framework for evaluating foreign clinical data for registration"
  },
  "E6": {
    title: "Good Clinical Practice",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5"],
    description: "Standards for designing, conducting, and reporting clinical trials"
  },
  "E7": {
    title: "Studies in Support of Special Populations: Geriatrics",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5", "2.7.3"],
    description: "Guidance on clinical studies in geriatric populations"
  },
  "E8": {
    title: "General Considerations for Clinical Trials",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5"],
    description: "Basic principles for clinical trials"
  },
  "E9": {
    title: "Statistical Principles for Clinical Trials",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5.3", "2.7.3"],
    description: "Statistical considerations for design, conduct, and analysis of clinical trials"
  },
  "E10": {
    title: "Choice of Control Group and Related Issues in Clinical Trials",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5", "2.5"],
    description: "Guidance on control group selection for clinical trials"
  },
  "E11": {
    title: "Clinical Investigation of Medicinal Products in the Pediatric Population",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5"],
    description: "Special considerations for pediatric clinical studies"
  },
  "E12": {
    title: "Principles for Clinical Evaluation of New Antihypertensive Drugs",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5"],
    description: "Specific recommendations for antihypertensive drug development"
  },
  "E14": {
    title: "Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.4"],
    description: "Guidance on clinical QT studies"
  },
  "E15": {
    title: "Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5"],
    description: "Standardized terminology for genomic biomarkers"
  },
  "E16": {
    title: "Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure and Format of Qualification Submissions",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5"],
    description: "Guidance on biomarker qualification submissions"
  },
  "E17": {
    title: "General Principles for Planning and Design of Multi-Regional Clinical Trials",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5"],
    description: "Planning and design of multi-regional clinical trials"
  },
  "E18": {
    title: "Genomic Sampling and Management of Genomic Data",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5"],
    description: "Collection, storage, and handling of genomic samples and data"
  },
  "E19": {
    title: "Optimization of Safety Data Collection",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5", "5.3.6"],
    description: "Selective approach to safety data collection in late-stage clinical trials"
  },
  "E20": {
    title: "Adaptive Clinical Trials",
    url: "https://ich.org/page/efficacy-guidelines",
    sections: ["5.3.5"],
    description: "Guidance on adaptive clinical trial designs"
  },
  
  // Multidisciplinary Guidelines
  "M1": {
    title: "Medical Dictionary for Regulatory Activities (MedDRA)",
    url: "https://ich.org/page/multidisciplinary-guidelines",
    sections: ["2.7.4", "5.3.5"],
    description: "Standardized medical terminology for regulatory activities"
  },
  "M2": {
    title: "Electronic Standards for Transmission of Regulatory Information",
    url: "https://ich.org/page/multidisciplinary-guidelines",
    sections: ["1.1"],
    description: "Electronic standards for regulatory information"
  },
  "M3": {
    title: "Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals",
    url: "https://ich.org/page/multidisciplinary-guidelines",
    sections: ["4.2", "2.4"],
    description: "Guidance on timing of nonclinical studies relative to clinical development"
  },
  "M4": {
    title: "The Common Technical Document",
    url: "https://ich.org/page/multidisciplinary-guidelines",
    sections: ["1.1", "2.1"],
    description: "Structure and organization of CTD for marketing applications"
  },
  "M5": {
    title: "Data Elements and Standards for Drug Dictionaries",
    url: "https://ich.org/page/multidisciplinary-guidelines",
    sections: ["2.3", "2.7"],
    description: "Standards for drug dictionaries to support medicinal product identification"
  },
  "M6": {
    title: "Gene Therapy",
    url: "https://ich.org/page/multidisciplinary-guidelines",
    sections: ["3.2", "4.2", "5.3"],
    description: "Development and evaluation of gene therapy products"
  },
  "M7": {
    title: "Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk",
    url: "https://ich.org/page/multidisciplinary-guidelines",
    sections: ["3.2.S.3.2", "3.2.P.5.5"],
    description: "Guidance on mutagenic impurities assessment and control"
  },
  "M8": {
    title: "Electronic Common Technical Document (eCTD)",
    url: "https://ich.org/page/multidisciplinary-guidelines",
    sections: ["1.1"],
    description: "Electronic specification for CTD submissions"
  },
  "M9": {
    title: "Biopharmaceutics Classification System-based Biowaivers",
    url: "https://ich.org/page/multidisciplinary-guidelines",
    sections: ["3.2.P.2", "5.3.1"],
    description: "Framework for biowaivers based on BCS"
  },
  "M10": {
    title: "Bioanalytical Method Validation and Study Sample Analysis",
    url: "https://ich.org/page/multidisciplinary-guidelines",
    sections: ["4.2.2.1", "5.3.1.4"],
    description: "Validation of bioanalytical methods for nonclinical and clinical studies"
  },
  "M11": {
    title: "Clinical electronic Structured Harmonized Protocol (CeSHarP)",
    url: "https://ich.org/page/multidisciplinary-guidelines",
    sections: ["5.3.5"],
    description: "Standardized structure and format for clinical protocols"
  },
  "M12": {
    title: "Drug Interaction Studies",
    url: "https://ich.org/page/multidisciplinary-guidelines",
    sections: ["4.2.2.6", "5.3.3.4"],
    description: "Evaluation of drug-drug interactions in drug development"
  },
  "M13": {
    title: "Bioequivalence for Immediate-Release Solid Oral Dosage Forms",
    url: "https://ich.org/page/multidisciplinary-guidelines",
    sections: ["5.3.1.2"],
    description: "Harmonized approach to bioequivalence studies"
  },
  "M14": {
    title: "Pediatric Extrapolation",
    url: "https://ich.org/page/multidisciplinary-guidelines",
    sections: ["5.3.5.3"],
    description: "Framework for extrapolating efficacy data to pediatric populations"
  }
};

/**
 * Get relevant ICH guidelines for a CTD section
 * @param {string} ctdSection - The CTD section ID (e.g., "3.2.S.2.1")
 * @returns {Array} Array of relevant guidelines with their descriptions
 */
export function mapCTDToGuidelines(ctdSection) {
  if (!ctdSection) return [];
  
  const relevantGuidelines = [];
  
  // First, exact match
  Object.keys(ichGuidelines).forEach(key => {
    const guideline = ichGuidelines[key];
    if (guideline.sections.includes(ctdSection)) {
      relevantGuidelines.push({
        id: key,
        title: `${key} - ${guideline.title}`,
        description: guideline.description,
        url: guideline.url
      });
    }
  });
  
  // Then, parent section matches (e.g., for 3.2.S.2.1, check guidelines for 3.2.S.2)
  if (ctdSection.includes('.')) {
    const parentSection = ctdSection.split('.').slice(0, -1).join('.');
    Object.keys(ichGuidelines).forEach(key => {
      const guideline = ichGuidelines[key];
      // Only add if not already added
      if (guideline.sections.includes(parentSection) && 
          !relevantGuidelines.some(g => g.id === key)) {
        relevantGuidelines.push({
          id: key,
          title: `${key} - ${guideline.title}`,
          description: guideline.description,
          url: guideline.url
        });
      }
    });
    
    // For very specific sections, check two levels up (e.g., for 3.2.S.2.1.1, also check guidelines for 3.2.S.2)
    if (parentSection.includes('.')) {
      const grandparentSection = parentSection.split('.').slice(0, -1).join('.');
      Object.keys(ichGuidelines).forEach(key => {
        const guideline = ichGuidelines[key];
        // Only add if not already added
        if (guideline.sections.includes(grandparentSection) && 
            !relevantGuidelines.some(g => g.id === key)) {
          relevantGuidelines.push({
            id: key,
            title: `${key} - ${guideline.title}`,
            description: guideline.description,
            url: guideline.url
          });
        }
      });
    }
  }
  
  // Finally, check for module-level guidelines
  if (ctdSection.match(/^[1-5]/)) {
    const moduleNum = ctdSection.charAt(0);
    Object.keys(ichGuidelines).forEach(key => {
      const guideline = ichGuidelines[key];
      // Only add if not already added
      if (key === `M${moduleNum}` && !relevantGuidelines.some(g => g.id === key)) {
        relevantGuidelines.push({
          id: key,
          title: `${key} - ${guideline.title}`,
          description: guideline.description,
          url: guideline.url
        });
      }
    });
  }
  
  return relevantGuidelines;
}

/**
 * Get all ICH guidelines
 * @returns {Object} Object containing all ICH guidelines
 */
export function getAllGuidelines() {
  return ichGuidelines;
}

/**
 * Search ICH guidelines based on keyword
 * @param {string} keyword - The keyword to search for
 * @returns {Array} Array of matching guidelines
 */
export function searchGuidelines(keyword) {
  if (!keyword) return [];
  
  const lowercaseKeyword = keyword.toLowerCase();
  const results = [];
  
  Object.keys(ichGuidelines).forEach(key => {
    const guideline = ichGuidelines[key];
    if (key.toLowerCase().includes(lowercaseKeyword) || 
        guideline.title.toLowerCase().includes(lowercaseKeyword) ||
        guideline.description.toLowerCase().includes(lowercaseKeyword)) {
      results.push({
        id: key,
        title: `${key} - ${guideline.title}`,
        description: guideline.description,
        url: guideline.url,
        sections: guideline.sections
      });
    }
  });
  
  return results;
}

/**
 * Get guidelines by category
 * @param {string} category - The category (Q, S, E, M)
 * @returns {Array} Array of guidelines in the specified category
 */
export function getGuidelinesByCategory(category) {
  if (!category || !['Q', 'S', 'E', 'M'].includes(category)) return [];
  
  const results = [];
  
  Object.keys(ichGuidelines).forEach(key => {
    if (key.startsWith(category)) {
      const guideline = ichGuidelines[key];
      results.push({
        id: key,
        title: `${key} - ${guideline.title}`,
        description: guideline.description,
        url: guideline.url,
        sections: guideline.sections
      });
    }
  });
  
  return results;
}

export default {
  mapCTDToGuidelines,
  getAllGuidelines,
  searchGuidelines,
  getGuidelinesByCategory
};